Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Effect of smoking cessation advice on cardiovascular disease.

Eddy DM, Peskin B, Shcheprov A, Pawlson G, Shih S, Schaaf D.

Am J Med Qual. 2009 May-Jun;24(3):241-9. doi: 10.1177/1062860609332509. Epub 2009 Mar 30.

PMID:
19332865
2.

The impact of prevention on reducing the burden of cardiovascular disease.

Kahn R, Robertson RM, Smith R, Eddy D.

Circulation. 2008 Jul 29;118(5):576-85. doi: 10.1161/CIRCULATIONAHA.108.190186. Epub 2008 Jul 7.

3.

The impact of prevention on reducing the burden of cardiovascular disease.

Kahn R, Robertson RM, Smith R, Eddy D.

Diabetes Care. 2008 Aug;31(8):1686-96. doi: 10.2337/dc08-9022. Review.

4.

Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.

Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S.

Clin Drug Investig. 2009;29(10):655-65. doi: 10.2165/11317730-000000000-00000.

PMID:
19715382
5.

Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness.

Solberg LI, Maciosek MV, Edwards NM, Khanchandani HS, Goodman MJ.

Am J Prev Med. 2006 Jul;31(1):62-71. Review.

PMID:
16777544
6.

Physician-delivered advice to quit smoking among Italian smokers.

Ferketich AK, Gallus S, Colombo P, Fossati R, Apolone G, Zuccaro P, La Vecchia C.

Am J Prev Med. 2008 Jul;35(1):60-3. doi: 10.1016/j.amepre.2008.03.022. Epub 2008 May 14.

PMID:
18482820
7.

Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan.

Igarashi A, Takuma H, Fukuda T, Tsutani K.

Pharmacoeconomics. 2009;27(3):247-61. doi: 10.2165/00019053-200927030-00007.

PMID:
19354344
8.

The economics of smoking and cardiovascular disease.

Lightwood J.

Prog Cardiovasc Dis. 2003 Jul-Aug;46(1):39-78. Review.

PMID:
12920700
10.

Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.

Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.

Can J Clin Pharmacol. 2009 Summer;16(2):e331-45. Epub 2009 Jun 16.

PMID:
19531812
11.

Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease.

Bullen C.

Expert Rev Cardiovasc Ther. 2008 Jul;6(6):883-95. doi: 10.1586/14779072.6.6.883. Review.

PMID:
18570625
12.
13.

Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?

Menzin J, Lines LM, Marton J.

Expert Rev Pharmacoecon Outcomes Res. 2009 Jun;9(3):257-64. doi: 10.1586/erp.09.28. Review.

PMID:
19527098
14.

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.

Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.

Curr Med Res Opin. 2009 May;25(5):1273-84. doi: 10.1185/03007990902869169 .

PMID:
19366302
15.

A pharmacoeconomic analysis of compliance gains on antipsychotic medications.

Damen J, Thuresson PO, Heeg B, Lothgren M.

Appl Health Econ Health Policy. 2008;6(4):189-97. doi: 10.2165/00148365-200806040-00002.

PMID:
19382819
16.

Trends in death rates from tobacco-related cardiovascular diseases in selected US states differing in tobacco-control efforts.

Polednak AP.

Epidemiology. 2009 Jul;20(4):542-6. doi: 10.1097/EDE.0b013e3181a39fe2.

PMID:
19367166
17.

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.

Arnold E, Yuan Y, Iloeje U, Cook G.

Appl Health Econ Health Policy. 2008;6(4):231-46. doi: 10.2165/00148365-200806040-00005.

PMID:
19382822
18.

Increasing smoking cessation care provision in hospitals: a meta-analysis of intervention effect.

Freund M, Campbell E, Paul C, Sakrouge R, McElduff P, Walsh RA, Wiggers J, Knight J, Girgis A.

Nicotine Tob Res. 2009 Jun;11(6):650-62. doi: 10.1093/ntr/ntp056. Epub 2009 May 7. Review.

PMID:
19423696
19.

Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.

Nuijten M, Andress DL, Marx SE, Sterz R.

Curr Med Res Opin. 2009 May;25(5):1221-34. doi: 10.1185/03007990902844097 .

PMID:
19335321
20.

An appraisal of smoking cessation aids.

Mundey K.

Curr Opin Pulm Med. 2009 Mar;15(2):105-12. doi: 10.1097/MCP.0b013e328321862e. Review.

PMID:
19532024

Supplemental Content

Support Center